No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon

J Infect Dis. 2009 Dec 1;200(11):1658-61. doi: 10.1086/647990.

Abstract

In the context of a trial studying intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Lambaréné, Gabon, children aged 18-30 months were followed up after having received their last dose at an age of 15 months. In the intention-to-treat population, the protective efficacy against all malaria episodes was -18.0 (95% confidence interval, -97.4 to 29.5; P = .529). The protective efficacy against first or only anemia episode was -45.3 (95% confidence interval, -234.5 to 36.3; P=.375). The protective efficacies were negative and were not statistically significant. These results do not appear to support the concept of a rebound effect after intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants. Clinical trials registration. NCT00167843.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / epidemiology
  • Anemia / prevention & control
  • Antimalarials / therapeutic use*
  • Child, Preschool
  • Cohort Studies
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Combinations
  • Gabon / epidemiology
  • Humans
  • Infant
  • Kaplan-Meier Estimate
  • Malaria / drug therapy
  • Malaria / epidemiology
  • Malaria / prevention & control*
  • Morbidity
  • Pyrimethamine / therapeutic use*
  • Sulfadoxine / therapeutic use*

Substances

  • Antimalarials
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Pyrimethamine

Associated data

  • ClinicalTrials.gov/NCT00167843